Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression
18 Years
N/A
Both
Pancreatic Cancer
Trial Information
Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression
OBJECTIVES:
Primary
- Compare the overall survival of patients with unresectable metastatic pancreatic cancer
treated with fluorouracil, leucovorin calcium, and cisplatin followed by gemcitabine
hydrochloride vs gemcitabine hydrochloride followed by fluorouracil, leucovorin
calcium, and cisplatin.
Secondary
- Compare progression-free survival of patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare the quality of life of patients treated with these regimens.
- Compare the percentage of these patients needing second-line therapy.
- Compare the duration of hospitalization of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to ECOG
performance status (0 or 1 vs 2), participating center, location of the tumor (ampullar
region vs other locations), and infusion rate of gemcitabine hydrochloride (30 vs 100
minutes). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive leucovorin calcium IV over 2 hours on day 1, cisplatin IV over
1 hour on day 1 or 2, and fluorouracil IV over 46 hours on day 1 and 2. Treatment
repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
Patients with disease progression also receive gemcitabine hydrochloride IV over 30 or
100 minutes weekly for 7 weeks. Patients then receive gemcitabine hydrochloride IV on
days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression
or unacceptable toxicity.
- Arm II: Patients receive gemcitabine hydrochloride IV over 30 or 100 minutes weekly for
7 weeks in the absence of disease progression or unacceptable toxicity. Patients with
disease progression receive fluorouracil, leucovorin calcium, and cisplatin as in arm
I.
Quality of life is assessed at baseline and then every 2 months.
After completion of study therapy, patients are followed periodically for 2 years.
PROJECTED ACCRUAL: A total of 202 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed adenocarcinoma of the pancreas or ampulla
- Metastatic disease
- Unresectable disease
- Measurable disease, meeting the following criteria:
- No prior radiotherapy to the only site of measurable disease
- Diameter > 10 mm by spiral CT scan or MRI OR > 20 mm by conventional methods
- No brain metastases
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy > 2 months
- No contraindication to chemotherapy
- Creatinine clearance > 60 mL/min
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Alkaline phosphatase < 5 times normal
- Bilirubin ≤ 3 mg/dL
- No coronary insufficiency
- No symptomatic cardiac disease
- Good hydration possible
- No Child-Pugh class B or C cirrhosis
- No other malignancy except for basal cell skin cancer or carcinoma in situ of the
cervix
- Not pregnant or nursing
- Negative pregnancy test
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior palliative or adjuvant chemotherapy
- At least 4 weeks since prior radiotherapy
- No radiotherapy during or for 4 weeks after study therapy
- No other concurrent anticancer therapy
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Primary Purpose: Treatment
Outcome Measure:
Overall survival
Safety Issue:
No
Principal Investigator
Jean-Francois Seitz, MD
Investigator Role:
Study Chair
Investigator Affiliation:
CHU de la Timone
Authority:
United States: Federal Government
Study ID:
CDR0000453841
NCT ID:
NCT00303758
Start Date:
October 2005
Completion Date:
Related Keywords:
- Pancreatic Cancer
- adenocarcinoma of the pancreas
- recurrent pancreatic cancer
- stage IV pancreatic cancer
- Pancreatic Neoplasms
Name | Location |
|---|
